A Phase 4 interventional study of nab-paclitaxel and Carboplatin in Non-Small Cell Lung Cancer, Carcinoma and Squamous Cell Carcinoma, sponsored by Celgene. Completed at 55 sites in United States. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2018-09-24.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 11 under way, 1 of them phase 3. Albumin-Bound Paclitaxel · Carcinoma, Non-Small-Cell Lung.
Among the 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung, this one is the 13th largest by enrollment, is one of 3 that started in 2014, is one of 2 in phase 4, and was the 17th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →8 of the 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
People's Hospital of Quzhou · Sites in China
Ages 18–75
Fox Chase Cancer Center · Sites in United States
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 18+
German Cancer Research Center
Ages 18+ · Women only
By country, each count listing its studies:
Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 33 · Phase 3 8 · Phase 4 2
First in 2003; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 143 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 64 across the 47 interventional studies. Of the 27 that completed or were terminated, 19 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 47 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb: 21 open now, 35 under way, 10 of them phase 3. Of 91 finished, 47 (52%) have results posted.
Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 57th largest by enrollment of the 107 interventional ones that give a count, is one of 7 that started in 2014, is one of 2 in phase 4, and was the 35th registered.
Bristol-Myers Squibb’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
1 of the studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04253964Wake Forest University Health SciencesPilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy | 2027-09-01 |
Add it to your calendar (.ics) → With an account.
Among the 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Bristol-Myers Squibb’s 131 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
Study comparing two regimens of nab-paclitaxel and carboplatin combination in elderly subjects (≥ 70 years old) with advanced NSCLC
This is a Phase IV, randomized, open-label, multicenter study of continuous weekly versus weekly times three with one-week break nab-paclitaxel in combination with carboplatin as first-line treatment in elderly subjects (≥ 70 years old) with advanced non small cell lung cancer who have not received prior chemotherapy for their advanced disease and are not candidates for curative surgery or radiation therapy. The primary study endpoint is the percentage of subjects with either peripheral neuropathy or myelosuppression adverse events. Patients will continue treatment until they develop progressive disease, unacceptable side-effects or wish to withdraw from the study, according to local standard of care. Patients will have radiographic evaluations every 6 weeks while on treatment.
Inclusion Criteria: -
Inclusion Criteria: -
Male subjects must: Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of while participating in the study, during dose interruptions and for 6 months following study drug discontinuation, even if he has undergone a successful vasectomy.
Exclusion Criteria:
Evidence of active , including (prior evidence of brain metastasis are permitted only if treated and stable and off therapy for ≥ 4 weeks prior to signing Informed consent form. Magnetic Resonance Imaging of the brain (or Computed Tomography scan w/contrast) is preferred for diagnosis.
11.History of interstitial lung disease, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, or pulmonary pneumonitis.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion over 30 minutes on Days 1, 8, and 15 and Carboplatin AUC = 6 mg\*min/mL IV following nab-paclitaxel infusion on Day 1 of every 21-day treatment cycle
Drug: nab-paclitaxel · Drug: Carboplatin
nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1, 8, and 15 of each 21-day treatment followed by one-week break and Carboplatin AUC = 6 mg\*min/mL IV following nab-paclitaxel infusion on Day 1 of each 21-day treatment followed by one-week break
Drug: nab-paclitaxel · Drug: Carboplatin
Also known as: Abraxane
Percentage of Participants With Either Peripheral Neuropathy ≥ Grade 2 or Myelosuppression Adverse Events (AEs) ≥ Grade 3 Based on Local Laboratory Values
Peripheral neuropathy (sensory or motor) assessment was done at screening, on Days 1, 8, 15 of every treatment cycle, at the End-of-Treatment visit and at the 28-day Follow-up Visit. Changes in neuropathy grade from baseline was reported as an AE as assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Myelosuppression in participants receiving chemotherapy may have manifested as neutropenia, thrombocytopenia, or anemia. Grade 3 neutropenia including an absolute neutropenia count (ANC) of 500 to 1,000 cells/mm\^3; anemia hemoglobain levels (Hgb) \<8.0 - 6.5 g/dL; \<4.9 - 4.0 mmol/L; \<80 - 65 g/L; transfusion indicated; and thrombocytopenia with platelet levels \<100,000 cells/mm\^3.
Time frame: From the date of the first dose of investigational product (IP) until 28 days after the last dose of IP; up to data cut-off date of 20 November 2016; The median treatment duration for Arms A and B were 3.04 months and 5.17 months respectively.
Number of Participants With Treatment Emergent Adverse Events During the Treatment Period
Treatment-emergent adverse events (TEAEs) were defined as any AE or serious adverse event (SAE) that occurred or worsened on or after the day of the first dose of the IP through 28 days after the last dose of IP. Any SAE with an onset date more than 28 day after the last dose of IP that was assessed by the investigator as related to IP was considered a TEAE. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and based on the scale: Grade 1 = Mild - transient or mild discomfort; Grade 2 = Moderate - mild to moderate limitation in activity, assistance may be needed; minimal medical intervention required; Grade 3 = Severe - marked limitation in activity, assistance usually required; medical intervention required, hospitalization is possible; Grade 4 = Life threatening - extreme limitation in activity, assistance required; medical intervention, hospitalization or hospice care probable; Grade 5 = death.
Time frame: From the date of the first dose of IP until 28 days after the last dose of IP; up to a later data cut-off date of 14 July 2017; maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively.
Percentage of Participants With at Least 1 Treatment Emergent Adverse Event With Action Taken as Study Drug Withdrawn
The percentage of participants with at least 1 TEAE with action taken as studydrug withdrawn during the treatment period of the trial was assessed throughout the conduct of the study. Study drug withdrawn (treatment permanently discontinued) was attributed to the part in which the onset of the adverse event took place.
Time frame: From the date of the first dose of IP until 28 days after the last dose of IP; up to a later data cut-off date of 14 July 2017 the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively
Dose Intensity Per Week of Nab-Paclitaxel During the Entire Study
Dose intensity was the cumulative dose divided by the dosing period in weeks.
Time frame: From day 1 of study treatment to the end date of study treatment; up to data cut off date of 20 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively
Dose Intensity Per Week of Carboplatin During the Entire Study
Dose intensity for carboplatin was the cumulative dose divided by the dosing period in weeks."
Time frame: From day 1 of study treatment to the end date of study treatment; up to data cut off date of 20 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively
Percentage of Participants With Dose Reductions During the Entire Study
A dose reduction occurred when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities.
Time frame: From the first dose of study treatment to discontinuation date of study treatment; up to date cut off date of 20 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively
Percentage of Participants With a Dose Delay During the Entire Study
A dose delay occurred when the dose assigned at a visit was held compared to the previous visit. Dose delays were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities.
Time frame: From the first dose of study treatment to discontinuation date of study treatment; up to date cut off date of 16 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively
Kaplan Meier Estimate of Progression-Free Survival (PFS)
Progression-free survival was defined as the time in months from day 1 of treatment to the date of disease progression based on the investigator's assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by radiological assessment) or death (any cause) on or prior to the clinical cut-off date, which ever occurred earlier. RECIST V1.1 criteria includes: - Complete Response (CR) is the disappearance of all target lesions; - Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions from baseline; - Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease (PD); - Progressive Disease is at least a 20% increase in the sum of diameters of target lesions from nadir
Time frame: From first dose of IP to the date of disease progression; up to a later clinical cut-off date of 14 July 2017; for Arms A and B participants were followed for PFS for 31 months and 20 months respectively
Kaplan Meier Estimate of Overall Survival (OS)
Overall survival was defined as the time in months between day 1 of treatment and death from any cause). Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off, whichever was earlier. Participants who were lost to follow-up prior to the end of the study or who were withdrawn from the study were censored at the time of last contact.
Time frame: From first dose of IP to the date of death due to any cause; up to a later clinical cut-off date of 14 July 2017; for Arms A and B participants were followed for OS for 31 months and 33 months respectively
Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST 1.1 Criteria
Overall response rate (ORR) was defined as the percentage of participants who had radiologic CR or PR compared to baseline (radiographic evaluation on the day of or within 28 days prior to randomization) according to RECIST Version 1.1 criteria as determined by the investigator, which was confirmed by repeated radiologic assessment performed no less than 28 days after the criteria for response were first met and occurred between Day 1 of treatment and the start of subsequent anticancer therapy, death or study discontinuation. A complete response and partial response per RECIST V 1.0 criteria was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of diameters of target lesions from baseline.
Time frame: From the first dose of IP to the date of documented first response; up to the data cut-off date of 14 July 2017; maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively.
This multicenter study was conducted in the United States and enrolled participants at a total of 41 sites.
| Milestone | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) |
|---|---|---|
| Started | 71 | 72 |
| Treated population | 68 | 70 |
| Completed | 1 | 1 |
| Not completed | 70 | 71 |
| Withdrew: Death | 2 | 3 |
| Withdrew: Adverse event | 17 | 14 |
| Withdrew: Progressive disease | 25 | 24 |
| Withdrew: Symptomatic deterioration | 2 | 10 |
| Withdrew: Withdrawal by subject | 13 | 11 |
| Withdrew: Miscellaneous | 8 | 7 |
| Withdrew: Participants randomized but not treated | 3 | 2 |
| Milestone | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) |
|---|---|---|
| Started | 58 | 55 |
| Completed | 19 | 18 |
| Not completed | 39 | 37 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Death | 37 | 34 |
Peripheral neuropathy (sensory or motor) assessment was done at screening, on Days 1, 8, 15 of every treatment cycle, at the End-of-Treatment visit and at the 28-day Follow-up Visit. Changes in neuropathy grade from baseline was reported as an AE as assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Myelosuppression in participants receiving chemotherapy may have manifested as neutropenia, thrombocytopenia, or anemia. Grade 3 neutropenia including an absolute neutropenia count (ANC) of 500 to 1,000 cells/mm\^3; anemia hemoglobain levels (Hgb) \<8.0 - 6.5 g/dL; \<4.9 - 4.0 mmol/L; \<80 - 65 g/L; transfusion indicated; and thrombocytopenia with platelet levels \<100,000 cells/mm\^3.
| Percentage of Participants | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) |
|---|---|---|
| Percentage of Participants With Either Peripheral Neuropathy ≥ Grade 2 or Myelosuppression Adverse Events (AEs) ≥ Grade 3 Based on Local Laboratory Values | 76.5 (64.6 to 85.9) | 77.1 (65.6 to 86.3) |
Treatment-emergent adverse events (TEAEs) were defined as any AE or serious adverse event (SAE) that occurred or worsened on or after the day of the first dose of the IP through 28 days after the last dose of IP. Any SAE with an onset date more than 28 day after the last dose of IP that was assessed by the investigator as related to IP was considered a TEAE. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and based on the scale: Grade 1 = Mild - transient or mild discomfort; Grade 2 = Moderate - mild to moderate limitation in activity, assistance may be needed; minimal medical intervention required; Grade 3 = Severe - marked limitation in activity, assistance usually required; medical intervention required, hospitalization is possible; Grade 4 = Life threatening - extreme limitation in activity, assistance required; medical intervention, hospitalization or hospice care probable; Grade 5 = death.
| Participants | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) |
|---|---|---|
| Treatment Emergent Adverse Event | 68 | 69 |
| Serious Treatment Emergent Adverse Event | 23 | 32 |
| Grade 3 or 4 Treatment Emergent Adverse Event | 60 | 59 |
| Grade 3 or Higher Treatment Emergent Adverse Event | 60 | 61 |
| Treatment Related TEAE | 65 | 66 |
| Treatment-Related Serious TEAE | 12 | 12 |
| TEAE with Action to Reduce or Interrupt IP Dose | 60 | 54 |
| Treatment-Related Action to Reduce/Interrupt IP | 56 | 51 |
| TEAE with Action Taken as Study Drug Withdrawn | 17 | 14 |
| Treatment-related TEAE with Action to Halt IP | 13 | 13 |
| TEAE with Fatal Outcome | 1 | 3 |
| Treatment-related TEAE with Fatal Outcome | 0 | 0 |
The percentage of participants with at least 1 TEAE with action taken as studydrug withdrawn during the treatment period of the trial was assessed throughout the conduct of the study. Study drug withdrawn (treatment permanently discontinued) was attributed to the part in which the onset of the adverse event took place.
| Percentage of Participants | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) |
|---|---|---|
| Percentage of Participants With at Least 1 Treatment Emergent Adverse Event With Action Taken as Study Drug Withdrawn | 25.0 | 20.0 |
Dose intensity was the cumulative dose divided by the dosing period in weeks.
| mg/m^2/week | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) |
|---|---|---|
| Dose Intensity Per Week of Nab-Paclitaxel During the Entire Study | 64.07 ± 17.374 | 56.57 ± 16.645 |
Dose intensity for carboplatin was the cumulative dose divided by the dosing period in weeks."
| mg*min/mL/week | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) |
|---|---|---|
| Dose Intensity Per Week of Carboplatin During the Entire Study | 1.51 ± 0.384 | 1.33 ± 0.671 |
A dose reduction occurred when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities.
| Percentage of Participants | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) |
|---|---|---|
| nab-Paclitaxel | 64.7 | 58.6 |
| Carboplatin | 57.4 | 58.6 |
A dose delay occurred when the dose assigned at a visit was held compared to the previous visit. Dose delays were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities.
| Percentage of Participants | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) |
|---|---|---|
| nab-Paclitaxel | 58.8 | 48.6 |
| Carboplatin | 52.9 | 44.3 |
Progression-free survival was defined as the time in months from day 1 of treatment to the date of disease progression based on the investigator's assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by radiological assessment) or death (any cause) on or prior to the clinical cut-off date, which ever occurred earlier. RECIST V1.1 criteria includes: - Complete Response (CR) is the disappearance of all target lesions; - Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions from baseline; - Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease (PD); - Progressive Disease is at least a 20% increase in the sum of diameters of target lesions from nadir
| months | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) |
|---|---|---|
| Kaplan Meier Estimate of Progression-Free Survival (PFS) | 3.88 (3.02 to 6.24) | 7.20 (5.85 to 11.53) |
Overall survival was defined as the time in months between day 1 of treatment and death from any cause). Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off, whichever was earlier. Participants who were lost to follow-up prior to the end of the study or who were withdrawn from the study were censored at the time of last contact.
| months | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) |
|---|---|---|
| Kaplan Meier Estimate of Overall Survival (OS) | 14.52 (9.46 to 17.28) | 14.98 (12.09 to 18.73) |
Overall response rate (ORR) was defined as the percentage of participants who had radiologic CR or PR compared to baseline (radiographic evaluation on the day of or within 28 days prior to randomization) according to RECIST Version 1.1 criteria as determined by the investigator, which was confirmed by repeated radiologic assessment performed no less than 28 days after the criteria for response were first met and occurred between Day 1 of treatment and the start of subsequent anticancer therapy, death or study discontinuation. A complete response and partial response per RECIST V 1.0 criteria was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of diameters of target lesions from baseline.
| Percentage of participants | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) |
|---|---|---|
| Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST 1.1 Criteria | 26.8 (16.9 to 38.6) | 41.7 (30.2 to 53.9) |
Collected over TEAEs are reported up to 37 months; from Day 1 of IP until 28 days after the last dose of IP and those SAEs made known to the Investigator at any time thereafter being suspected of being related to IP; up data cut-off date of 14 July 2017.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | 45/71 (63.4%) | 23/68 (33.8%) | 68/68 (100%) |
| Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) | 46/72 (63.9%) | 32/70 (45.7%) | 69/70 (98.6%) |
| Event | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 6/68 | 3/70 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/68 | 6/70 |
| PneumoniaInfections and infestations | 2/68 | 5/70 |
| DiarrhoeaGastrointestinal disorders | 4/68 | 2/70 |
| Atrial fibrillationCardiac disorders | 1/68 | 3/70 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/68 | 1/70 |
| VomitingGastrointestinal disorders | 2/68 | 2/70 |
| DehydrationMetabolism and nutrition disorders | 2/68 | 2/70 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 2/68 | 0/70 |
| SyncopeNervous system disorders | 2/68 | 2/70 |
| Event | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) |
|---|---|---|
| FatigueGeneral disorders | 46/68 | 37/70 |
| AnaemiaBlood and lymphatic system disorders | 45/68 | 39/70 |
| Peripheral sensory neuropathyNervous system disorders | 40/68 | 30/70 |
| NauseaGastrointestinal disorders | 32/68 | 37/70 |
| NeutropeniaBlood and lymphatic system disorders | 35/68 | 32/70 |
| ThrombocytopeniaBlood and lymphatic system disorders | 30/68 | 19/70 |
| DiarrhoeaGastrointestinal disorders | 29/68 | 26/70 |
| AlopeciaSkin and subcutaneous tissue disorders | 27/68 | 29/70 |
| Decreased appetiteMetabolism and nutrition disorders | 22/68 | 26/70 |
| ConstipationGastrointestinal disorders | 25/68 | 20/70 |
Intent to Treat Population included all randomized participants regardless of whether the participant received any study drug or had any efficacy assessments performed.
| Age, Continuous(years) | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) | Total |
|---|---|---|---|
| Mean | 76.7 ± 4.13 | 76.4 ± 5.18 | 76.6 ± 4.67 |
| Age, Customized(Participants) | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) | Total |
|---|---|---|---|
| 70-74 years | 20 | 33 | 53 |
| 75-79 years | 30 | 18 | 48 |
| 80-84 years | 19 | 17 | 36 |
| 85-89 years | 2 | 2 | 4 |
| ≥ 90 years | 0 | 2 | 2 |
| Sex: Female, Male(Participants) | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) | Total |
|---|---|---|---|
| Female | 30 | 32 | 62 |
| Male | 41 | 40 | 81 |
| Race/Ethnicity, Customized(Participants) | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 3 | 3 |
| Black or African American | 3 | 7 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| White | 64 | 57 | 121 |
| Other | 1 | 1 | 2 |
| Data Missing | 3 | 2 | 5 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)(Participants) | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) | Total |
|---|---|---|---|
| 0 = Fully Active | 21 | 20 | 41 |
| 1 = Restricted in Physical Activity; Ambulatory | 50 | 52 | 102 |
| 2 = Ambulatory and Capable of All Self-care | 0 | 0 | 0 |
| 3 = Capable of Only Limited Self-care | 0 | 0 | 0 |
| 4 = Completely Disabled. | 0 | 0 | 0 |
| Confirmed Histology(Participants) | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) | Total |
|---|---|---|---|
| Squamous Cell Carcinoma | 27 | 28 | 55 |
| Non-Squamous Cell Carcinoma | 44 | 44 | 88 |
| Stage of Disease at Enrollment(Participants) | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) | Total |
|---|---|---|---|
| IIIa | 4 | 5 | 9 |
| IIIb | 6 | 8 | 14 |
| IV | 60 | 59 | 119 |
| Data Missing | 1 | 0 | 1 |
| Number of Prior Systemic Anticancer Therapies for Non-Small Cell Lung Cancer (NSCLC)(Therapies) | Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) | Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) | Total |
|---|---|---|---|
| Median | 2.0 (1.0 to 2.0) | 2.0 (2.0 to 4.0) | 2.0 (1.0 to 4.0) |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2014 to primary completion in Jul 2017, 37 months.
Results were first posted in Sep 2018, 1 year 2 months after primary completion.
Of 43 phase 4 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's 37 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Albumin-Bound Paclitaxel · Carboplatin
Carcinoma, Non-Small-Cell Lung →